Eli Lilly tops new biopharma ranking on launch success, development speed

Flush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella’s inaugural Pipeline-to-Patient Productivity Index, which evaluated 25 large, global biopharma companies on R&D productivity, market access and commercial performance.